52.06
price down icon5.33%   -2.93
after-market After Hours: 52.39 0.33 +0.63%
loading
Korro Bio Inc stock is traded at $52.06, with a volume of 39,187. It is down -5.33% in the last 24 hours and down -17.67% over the past month. Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
See More
Previous Close:
$54.99
Open:
$55.11
24h Volume:
39,187
Relative Volume:
0.34
Market Cap:
$487.71M
Revenue:
-
Net Income/Loss:
$-81.17M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-82.84M
1W Performance:
-0.48%
1M Performance:
-17.67%
6M Performance:
+4.14%
1Y Performance:
+29.57%
1-Day Range:
Value
$51.89
$56.04
1-Week Range:
Value
$48.71
$56.69
52-Week Range:
Value
$30.00
$98.00

Korro Bio Inc Stock (KRRO) Company Profile

Name
Name
Korro Bio Inc
Name
Phone
617-468-1999
Name
Address
60 FIRST STREET, CAMBRIDGE
Name
Employee
101
Name
Twitter
Name
Next Earnings Date
2024-12-08
Name
Latest SEC Filings
Name
KRRO's Discussions on Twitter

Compare KRRO with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
KRRO
Korro Bio Inc
52.06 487.71M 0 -81.17M -82.84M -10.13
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
468.13 120.56B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
750.22 82.44B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
616.55 36.87B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
253.07 32.64B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
118.39 28.38B 3.30B -501.07M 1.03B -2.1146

Korro Bio Inc Stock (KRRO) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-21-24 Initiated Raymond James Strong Buy
Aug-14-24 Initiated William Blair Outperform
Mar-28-24 Reiterated H.C. Wainwright Buy
Feb-27-24 Initiated BMO Capital Markets Outperform
Dec-04-23 Initiated H.C. Wainwright Buy
Nov-29-23 Initiated RBC Capital Mkts Outperform
Nov-10-23 Initiated Piper Sandler Overweight
Feb-15-23 Downgrade Chardan Capital Markets Buy → Neutral
Feb-13-23 Downgrade Cowen Outperform → Market Perform
Sep-22-21 Downgrade Goldman Buy → Neutral
Jan-27-21 Upgrade JP Morgan Neutral → Overweight
Dec-22-20 Initiated B. Riley Securities Buy
Jul-14-20 Initiated Oppenheimer Outperform
May-18-20 Downgrade JP Morgan Overweight → Neutral
Oct-28-19 Initiated Cowen Outperform
Oct-28-19 Initiated Goldman Buy
Oct-28-19 Initiated JP Morgan Overweight
View All

Korro Bio Inc Stock (KRRO) Latest News

pulisher
09:46 AM

Eventide Asset Management LLC Lowers Stock Holdings in Korro Bio, Inc. (NASDAQ:KRRO) - MarketBeat

09:46 AM
pulisher
Nov 26, 2024

Korro Bio, Inc Receives Approval from the Australian Bellberry Human Research Ethics Committee and Clearance from the Australian Therapeutic Goods Administration to Initiate A Phase 1/2A Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency - Marketscreener.com

Nov 26, 2024
pulisher
Nov 26, 2024

Korro Bio's SWOT analysis: RNA editing stock poised for growth amid AATD treatment race - Investing.com

Nov 26, 2024
pulisher
Nov 24, 2024

HC Wainwright Reaffirms Buy Rating for Korro Bio (NASDAQ:KRRO) - Defense World

Nov 24, 2024
pulisher
Nov 23, 2024

Korro Bio (NASDAQ:KRRO) Trading 9.3% HigherHere's What Happened - MarketBeat

Nov 23, 2024
pulisher
Nov 22, 2024

Korro Bio (NASDAQ:KRRO) Receives Buy Rating from HC Wainwright - MarketBeat

Nov 22, 2024
pulisher
Nov 21, 2024

Korro to Participate in Upcoming Investor Conferences - The Manila Times

Nov 21, 2024
pulisher
Nov 21, 2024

Korro Bio CEO to Present at Major Healthcare Conferences in December | KRRO Stock News - StockTitan

Nov 21, 2024
pulisher
Nov 21, 2024

Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency - The Manila Times

Nov 21, 2024
pulisher
Nov 21, 2024

Korro Bio Gains Approval for Phase 1/2a AATD Treatment Trial, Shows Strong Preclinical Data | KRRO Stock News - StockTitan

Nov 21, 2024
pulisher
Nov 18, 2024

Jones Trading bullish on Korro Bio stock amid RNA editing and AATD prospects - Investing.com

Nov 18, 2024
pulisher
Nov 18, 2024

Korro Bio FY2024 EPS Forecast Increased by HC Wainwright - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

William Blair Has Positive View of Korro Bio FY2024 Earnings - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

Jones Trading Initiates Coverage of Korro Bio (KRRO) with Buy Recommendation - MSN

Nov 18, 2024
pulisher
Nov 15, 2024

Korro Bio, Inc. (NASDAQ:KRRO) Given Consensus Rating of "Buy" by Analysts - MarketBeat

Nov 15, 2024
pulisher
Nov 14, 2024

Eventide Asset Management's Strategic Reduction in Korro Bio Inc Holdings - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Deep Track Capital, LP's Strategic Acquisition of Korro Bio Inc Shares - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Korro to Present at the Jefferies London Healthcare Conference - The Manila Times

Nov 14, 2024
pulisher
Nov 14, 2024

Korro Bio to Present RNA-Editing Breakthroughs at Jefferies London Healthcare Conference | KRRO Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 13, 2024

Korro Bio’s Progress and Financial Updates - TipRanks

Nov 13, 2024
pulisher
Nov 13, 2024

Korro Bio's SWOT analysis: RNA editing pioneer's stock poised for growth - Investing.com

Nov 13, 2024
pulisher
Nov 13, 2024

William Blair Reiterates "Outperform" Rating for Korro Bio (NASDAQ:KRRO) - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates - The Manila Times

Nov 13, 2024
pulisher
Nov 13, 2024

FMR LLC Reduces Stake in Korro Bio Inc - GuruFocus.com

Nov 13, 2024
pulisher
Nov 12, 2024

Korro Bio CFO Vineet Agarwal sells $56,000 in stock - Investing.com

Nov 12, 2024
pulisher
Nov 12, 2024

Korro Bio CFO Vineet Agarwal sells $56,000 in stock By Investing.com - Investing.com UK

Nov 12, 2024
pulisher
Nov 12, 2024

Korro Bio Partners with Novo Nordisk, Reports $169M Cash Position Despite Widening Losses | KRRO Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 08, 2024

4 Biotech Stocks With AI, Machine Learning Prowess - Investing.com

Nov 08, 2024
pulisher
Nov 07, 2024

Korro Bio (NASDAQ:KRRO) Stock Price Up 10.9%Here's What Happened - MarketBeat

Nov 07, 2024
pulisher
Nov 05, 2024

Korro Bio files in Australia to begin first-in-human study of KRRO-110 for AATD - BioWorld Online

Nov 05, 2024
pulisher
Nov 04, 2024

Korro Bio (NASDAQ:KRRO) Shares Gap DownHere's Why - MarketBeat

Nov 04, 2024
pulisher
Nov 04, 2024

Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board - The Manila Times

Nov 04, 2024
pulisher
Nov 04, 2024

Korro Bio, Inc. Announces Submission to Bellberry HREC for Phase 1/2 Clinical Study of KRRO-110 for AATD - Marketscreener.com

Nov 04, 2024
pulisher
Oct 28, 2024

Korro Bio (NASDAQ:KRRO) Trading Down 5.1%Time to Sell? - MarketBeat

Oct 28, 2024
pulisher
Oct 25, 2024

Korro Bio's SWOT analysis: RNA editing pioneer's stock poised for clinical leap - Investing.com India

Oct 25, 2024
pulisher
Oct 24, 2024

Korro Bio's SWOT analysis: RNA editing pioneer's stock poised for clinical leap By Investing.com - Investing.com South Africa

Oct 24, 2024
pulisher
Oct 23, 2024

Korro Bio (NASDAQ:KRRO) Sees Large Volume IncreaseStill a Buy? - MarketBeat

Oct 23, 2024
pulisher
Oct 23, 2024

Korro Bio (NASDAQ:KRRO) Coverage Initiated at Raymond James - Defense World

Oct 23, 2024
pulisher
Oct 22, 2024

RBC lifts Korro Bio stock target on positive RNA editing outlook - Investing.com Australia

Oct 22, 2024
pulisher
Oct 22, 2024

Raymond James Initiates Coverage of Korro Bio (KRRO) with Strong Buy Recommendation - MSN

Oct 22, 2024
pulisher
Oct 21, 2024

Korro Bio price target raised to $105 from $95 at RBC Capital - TipRanks

Oct 21, 2024
pulisher
Oct 21, 2024

RBC lifts Korro Bio stock target on positive RNA editing outlook By Investing.com - Investing.com South Africa

Oct 21, 2024
pulisher
Oct 21, 2024

Royal Bank of Canada Boosts Korro Bio (NASDAQ:KRRO) Price Target to $105.00 - MarketBeat

Oct 21, 2024
pulisher
Oct 21, 2024

Korro Bio initiated with a Strong Buy at Raymond James - TipRanks

Oct 21, 2024
pulisher
Oct 21, 2024

Korro Bio, Inc. (NASDAQ:KRRO) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat

Oct 21, 2024
pulisher
Oct 21, 2024

Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space. - Investor's Business Daily

Oct 21, 2024
pulisher
Oct 19, 2024

Korro bio CFO Vineet Agarwal sells $799,526 in stock - Investing.com India

Oct 19, 2024
pulisher
Oct 18, 2024

Insider Selling: Korro Bio, Inc. (NASDAQ:KRRO) CFO Sells 10,216 Shares of Stock - MarketBeat

Oct 18, 2024
pulisher
Oct 18, 2024

Korro bio CFO Vineet Agarwal sells $799,526 in stock By Investing.com - Investing.com Australia

Oct 18, 2024

Korro Bio Inc Stock (KRRO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$21.50
price up icon 1.61%
$74.59
price down icon 1.14%
$370.49
price down icon 2.02%
$43.06
price down icon 0.76%
$215.00
price up icon 4.29%
$118.39
price down icon 1.93%
Cap:     |  Volume (24h):